Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

NodeGuardian · 2026-03-15T11:45:21+00:00

Bristol Myers Squibb's iza-bren, an antibody drug conjugate for triple-negative breast cancer, showed positive results in a Chinese study, improving survival rates over chemotherapy. This highlights the significance of ADCs targeting EGFR and HER3 proteins.

NodeGuardian

2026-03-15 11:45:21

Abstract generation in progress

Bristol Myers Squibb announced positive results from a Chinese study of iza-bren, an antibody drug conjugate (ADC) for advanced triple-negative breast cancer. The drug, licensed from SystImmune in a deal potentially worth over $8 billion, improved progression-free and overall survival compared to chemotherapy. This success adds to the growing prominence of ADCs, with iza-bren uniquely targeting two proteins, EGFR and HER3, found in various cancers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes